Isopto

Pilocarpine Hydrochloride, the active ingredient in Isopto, is a cholinergic agonist (miotic agent) presented as an ophthalmic solution for ocular use. It treats open‑angle glaucoma, ocular hypertension, and is employed to induce miosis for diagnostic procedures. GNH USA supplies Isopto as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Isopto acts on the ocular drainage pathway to lower intra‑ocular pressure in glaucoma and related conditions.

Open‑angle glaucoma: reduces intra‑ocular pressure by increasing trabecular outflow. Ocular hypertension: lowers intra‑ocular pressure to prevent progression to glaucoma. Induced miosis for diagnostic procedures: constricts the pupil to facilitate eye examinations and surgeries.

Common Side Effects: - Blurred vision shortly after instillation. - Eye irritation or burning sensation. - Headache or brow ache. - Increased tearing or photophobia.

Serious or Rare Side Effects: - Severe allergic reaction (e.g., swelling, rash, difficulty breathing). - Acute angle‑closure glaucoma in susceptible eyes. - Corneal ulceration or persistent myopia.

Isopto should be used with careful monitoring and adherence to clinical guidelines. - Monitor intra‑ocular pressure regularly: ensure therapeutic response and detect over‑reduction. - Use with caution in narrow‑angle glaucoma: risk of precipitating angle‑closure. - Avoid in patients with known hypersensitivity to pilocarpine or formulation components. - Adjust use in severe ocular inflammation: may exacerbate symptoms. - Store at room temperature: keep in original container, protect from light and moisture.

Isopto may interact with other ocular or systemic agents.

Major Interactions (Avoid): - Non‑selective beta‑blockers: may diminish IOP‑lowering effect. - Systemic anticholinergics: oppose pilocarpine’s muscarinic activity. - Other miotic agents (e.g., physostigmine): risk of excessive miosis.

Moderate Interactions (Monitor Closely): - Topical NSAIDs: increased risk of ocular irritation. - Carbonic anhydrase inhibitors: additive IOP reduction, monitor pressure. - Systemic cholinesterase inhibitors: may potentiate muscarinic effects.